Mankind Pharma Ltd Financial Statement
*All values are in Rs. Cr
| Particulars | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|
| Revenue | 2,345.91 | 2,484.78 | 2,667.49 |
| Operating Expense | 1,649.67 | 1,668.31 | 1,777.71 |
| Net Profit | 382.46 | 412.02 | 634.43 |
| Net Profit Margin | 16.30 | 16.58 | 23.78 |
| Earning Per Share | 9.27 | 10.35 | 15.84 |
| EBIDTA | 743.02 | 839.25 | 853.00 |
| Effective Tax Rate | 13.37 | 16.64 | 14.75 |
| Particulars | Mar 2025 |
|---|---|
| Revenue | 2345.91 |
| Operating Expense | 1649.67 |
| Net Profit | 382.46 |
| Net Profit Margin | 16.30 |
| Earning Per Share | 9.27 |
| EBIDTA | 743.02 |
| Effective Tax Rate | 13.37 |
*All values are in Rs. Cr
Standalone
Consolidated
| Particulars | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|
| Total Revenue Annual | 9,497.80 | 8,629.25 | 8,127.15 |
| Operating Expenses Annual | 6,935.25 | 6,362.96 | 6,429.77 |
| Operating Profit Annual | 3,116.99 | 2,640.32 | 1,860.16 |
| Interest Annual | 371.76 | 16.33 | 27.75 |
| Depreciation | 194.13 | 173.08 | 111.13 |
| Net Profit Annual | 1,884.25 | 1,772.63 | 1,248.26 |
| Tax Annual | 421.74 | 412.57 | 314.58 |
| Particulars | Mar 2025 |
|---|---|
| Total Revenue Annual | 9,497.80 |
| Operating Expenses Annual | 6,935.25 |
| Operating Profit Annual | 3,116.99 |
| Interest Annual | 371.76 |
| Depreciation | 194.13 |
| Net Profit Annual | 1,884.25 |
| Tax Annual | 421.74 |
*All values are in Rs. Cr
Standalone
Consolidated
| Particulars | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|
| Cash Flow at the Beginning | 211.62 | 145.46 | 86.17 |
| Cash Flow from Operations | 2,322.16 | 1,736.08 | 1,798.99 |
| Cash Flow from Investing | -12,178.83 | -1,665.19 | -1,040.61 |
| Cash Flow from Financing | 9,845.34 | -4.73 | -710.41 |
| Cash Flow at the End | 200.29 | 211.62 | 134.13 |
| Particulars | Mar 2025 |
|---|---|
| Cash Flow at the Beginning | 211.62 |
| Cash Flow from Operations | 2,322.16 |
| Cash Flow from Investing | -12,178.83 |
| Cash Flow from Financing | 9,845.34 |
| Cash Flow at the End | 200.29 |
*All values are in Rs. Cr
Standalone
Consolidated
| Particulars | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|
| PBDIT Margin (%) | 28.95 | 27.90 | 22.89 |
| PBIT Margin (%) | 24.97 | 24.02 | 19.58 |
| PBT Margin (%) | 24.90 | 22.60 | 18.89 |
| Net PROFIT Margin (%) | 20.48 | 21.74 | 15.36 |
| Return On Networth / Equity (%) | 13.89 | 20.25 | 17.43 |
| Return On Networth /Employed (%) | 14.88 | 23.35 | 20.91 |
| Return On Assets (%) | 12.29 | 21.09 | 16.43 |
| Total Debt / Equity (X) | 0.30 | TBA | 0.05 |
| Asset Turnover Ratio (%) | 0.60 | 0.97 | 1.07 |
| Particulars | Mar 2025 |
|---|---|
| PBDIT Margin (%) | 28.95 |
| PBIT Margin (%) | 24.97 |
| PBT Margin (%) | 24.90 |
| Net PROFIT Margin (%) | 20.48 |
| Return On Networth / Equity (%) | 13.89 |
| Return On Networth /Employed (%) | 14.88 |
| Return On Assets (%) | 12.29 |
| Total Debt / Equity (X) | 0.30 |
| Asset Turnover Ratio (%) | 0.60 |
*All values are in Rs. Cr
Standalone
Consolidated
| Particulars | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|
| Fixed Assets Annual | 3,486.82 | 3,620.98 | 3,193.85 |
| Total Current Assets Annual | 4,696.01 | 5,629.55 | 3,516.91 |
| Non Current Assets Annual | 19,132.31 | 5,886.84 | 5,854.21 |
| Total Shareholders Funds Annual | 14,640.27 | 9,702.77 | 7,783.91 |
| Total Assets Annual | 23,828.32 | 11,516.39 | 9,371.12 |
| Particulars | Mar 2025 |
|---|---|
| Fixed Assets Annual | 3,486.82 |
| Total Current Assets Annual | 4,696.01 |
| Non Current Assets Annual | 19,132.31 |
| Total Shareholders Funds Annual | 14,640.27 |
| Total Assets Annual | 23,828.32 |
EPS (INR)
Expected
10.20
Reported
10.19
Surprise
-0.10%
Dec 2024
EPS beaten by -0.10%
Sep 2024
EPS beaten by -0.32%
Jun 2024
EPS beaten by 0.00%
